Huge scope for Indian pharma as FDA eases drug scrutiny over shortage in US

Injectibles account for 60% of crunch; most plants under American regulator's lens the past two months have now received positive outcomes

Most Indian pharma plants that were inspected by the US drug regulator in the last few months or so have received positive outcomes.
 

As drug majors in the country have gradually improved compliance, against the backdrop of high shortages in the US, analysts see this as a positive sign for pharma exports.
 

Drug shortages have remained high this year in the US and the CLSA noted that the issue seems to be exacerbated when it comes to injectable products, which account for over 60 per cent of the current drug shortages. India accounts for roughly 30 per cent of the